Jingyu Zhang

Dr. Jingyu Zhang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
AYA Yang
A Yang
LLL Lin
L Lin
JZJingyu Zhang
Jingyu Zhang
YWYi Wu
Yi Wu
ZZZ Zhao
Z Zhao
The family of protein disulphide isomerases (PDIs) is a group of oxidoreductases that catalyze the oxidation, reduction and isomerization of disulphide bonds. Recent studies have shown that overexpression of one of the family enzymes, ERp46, potentiates arthritis severity, suggesting that the PDI family participates in arthritis pathogenesis. This study investigated the role of another PDI member, ERp72, in autoantibody-induced arthritis. Using the Cre-LoxP method, a mouse strain lacking ERp72 (ERp72-/- mice) was generated. Autoantibody-induced arthritis was induced in both ERp72-/- and ERp72+/+ control mice by injecting serum from K/BxN mice. The synovial inflammation severity was evaluated by joint diameter measurements and histological analysis. Proinflammatory cytokines expression in joint tissue and plasma was assessed by quantitative real-time PCR and ELISA. : The absence of ERp72 in the joints, white blood cells, spleen, thymus, and bone marrow of ERp72-/- mice was confirmed. In the K/BxN serum transfer-induced arthritis (STIA) model, ERp72-/- mice exhibited exacerbated arthritis compared to ERp72+/+ mice, with greater joint swelling, bone and cartilage erosion, and synovial inflammation. Furthermore, ERp72-/- mice exhibited increased expression of IL-1β, IL-6 and TNF-α in inflamed joint tissues and higher IL-6 levels in plasma. Conversely, IL-10 levels were lower in ERp72-/- mice inflamed joints than in ERp72+/+ mice. Notably, the basal TNF-α level in the blood of ERp72-/- mice was significantly higher than in ERp72+/+ mice. ERp72 plays a key role in the negative regulation of autoantibody-induced arthritis.

27 February 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
CHChao He
Chao He
AYAizhen Yang
Aizhen Yang
KLKeyu Lv
Keyu Lv
YZYuxin Zhang
Yuxin Zhang
ZZZhenzhen Zhao
Zhenzhen Zhao
YWYi Wu
Yi Wu
Thiol isomerases regulate the thiol-disulfide exchange of functional proteins in cells. Using genetically modified mouse models and inhibitors, we and others demonstrated that 7 thiol isomerases (ERp57, protein diisulfide isomerase, ERp72, ERp46, ERp5, TMX4, and TMX1) participate in thrombosis. There are 21 thiol isomerases in mammals, but whether other enzymes of this family also contribute to thrombosis remains unknown. Investigate whether and how ERp18 participates in arterial thrombosis. ERp18 knockout mice and arterial thrombosis models were used to determine the role of ERp18 in thrombosis. Platelets from ERp18 knockout mice were used to detect aggregation, activation, spreading, and clot retraction. Finally, flow cytometry and immunoprecipitation were used to detect the binding between ERp18 and αIIbβ3. The mice lacking ERp18 exhibited a prolonged tail bleeding time and decreased platelet thrombus formation in FeCl3-induced carotid arterial injury and laser-induced cremaster artery injury models. ERp18 deficiency inhibited platelet aggregation, adenosine triphosphate release, integrin αIIbβ3 activation, P-selectin expression, platelet adhesion, as well as clot retraction. Flow cytometry and coimmunoprecipitation analyses revealed that ERp18 binds to the platelet surface via interaction with integrin αIIbβ3. Moreover, the ERp18 protein promoted the binding of integrin αIIbβ3 to fibrinogen and platelet aggregation. Furthermore, the recombinant ERp18 protein exhibited reductase activity and cleaved integrin αIIbβ3 disulfides. ERp18 participates in platelet activation and thrombosis. Its function is, at least in part, through the regulation of integrin αIIbβ3 function. This finding expands our understanding of the role of thiol isomerases in the redox regulation of thrombosis and platelet function.

23 May 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
XWXiaoying Wang
Xiaoying Wang
AYAizhen Yang
Aizhen Yang
SHShuyi Huang
Shuyi Huang
ZZZhenzhen Zhao
Zhenzhen Zhao
FMFutian Ma
Futian Ma
JZJingyu Zhang
Jingyu Zhang

25 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
YZYuxin Zhang
Yuxin Zhang
YZYingkun Zhang
Yingkun Zhang
AYAizhen Yang
Aizhen Yang
YZYabei Zuo
Yabei Zuo
XYXiaofeng Yan
Xiaofeng Yan
JZJingyu Zhang
Jingyu Zhang
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet the contribution of specific VWF domains to its pathogenesis remains incompletely understood. In particular, the role of the D4 domain in VWF secretion, intracellular maturation, and multimer formation has not been fully elucidated. Here, we investigated the functional impact of a heterozygous p.Cys2163Tyr variant located in the D4 domain, identified in a patient with a severe bleeding phenotype, using clinical evaluation, genetic analysis, family studies, and in vitro expression assays. Laboratory testing revealed markedly reduced VWF:Ag (6.8 IU/dL), VWF:GPIbR (0.1 IU/dL), and FVIII:C levels, indicating a severe VWD phenotype in the proband. Plasma VWF multimer analysis showed a markedly reduced overall VWF signal with an almost complete absence of high-molecular-weight multimers, supporting classification of the phenotype as severe type 2A VWD. The heterozygous c.6488G>A (p.Cys2163Tyr) variant was also present in asymptomatic family members, indicating incomplete segregation with the severe phenotype and suggesting that this variant alone is insufficient to explain the proband’s disease severity. Notably, the proband’s mother exhibited mildly reduced VWF levels in the absence of this variant, suggesting the possible contribution of an additional unidentified defect or modifier affecting the maternal allele. In vitro expression demonstrated preserved intracellular VWF antigen, markedly reduced secretion of mutant VWF, and loss of high-molecular-weight VWF multimers. Together, these findings indicate that VWF p.Cys2163Tyr is a functionally deleterious variant that markedly impairs VWF secretion and high-molecular-weight multimer formation in vitro. However, the incomplete segregation observed in the family suggests that this heterozygous variant alone may not fully account for the proband’s severe type 2A VWD phenotype.


28 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YGYujie Guo
Yujie Guo
FZFeifei Zhang
Feifei Zhang
YZYabei Zuo
Yabei Zuo
YWYan Wang
Yan Wang
ZNZhiyun Niu
Zhiyun Niu
JZJingyu Zhang
Jingyu Zhang
Introduction: Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic disorder characterized by neutralizing autoantibodies against coagulation factor VIII (FVIII). First-line immunosuppressive therapy with corticosteroids with or without rituximab achieves complete remission (CR) in 60-80% of patients; however, relapse occurs in approximately 15-33% of cases after treatment cessation. Management of relapsed AHA remains challenging, with limited evidence for optimal second-line approaches. Bruton’s tyrosine kinase (BTK) inhibitors have emerged as promising agents for antibody-mediated autoimmune diseases. Case description: Herein, we report the first case of relapsed AHA successfully treated with orelabrutinib monotherapy after relapse following an initial response to a conventional corticosteroid-rituximab regimen. A 45-year-old male with type 1 diabetes mellitus and hyperthyroidism presented with spontaneous bleeding and was diagnosed with AHA associated with underlying autoimmune endocrinopathies. He achieved complete remission (CR) following prednisone and rituximab but relapsed 3 months after treatment cessation. Orelabrutinib 50 mg orally once daily was initiated as an experimental off-label approach. The patient demonstrated progressive laboratory improvement, achieving a second CR approximately 2 months after orelabrutinib initiation, with undetectable FVIII inhibitor and normalized FVIII activity. Sustained on-treatment remission was maintained throughout 5 months of therapy without bleeding episodes or adverse events, and remission has been maintained after completion of the planned 6-month course and subsequent treatment discontinuation. Conclusion: This case supports the therapeutic potential of selective BTK inhibition as a targeted, steroid-sparing strategy in relapsed AHA and highlights the need for prospective clinical trials to validate this approach.